… who received nirmatrelvir/ritonavir was conducted. We included eligible kidney transplant
recipients who developed COVID-19 and were treated with nirmatrelvir/ritonavir from March 31…

… of nirmatrelvir/ritonavir (150 mg/100 mg twice a day) in four patients with ESRD undergoing
hemodialysis. Nirmatrelvir … and hepatic tolerance of nirmatrelvir and ritonavir treatment in four …

… ]; nirmatrelvir (NMV) combined with ritonavir (NMV/r) is assessed in phase 3 trials as an
early therapeutic agent for patients at risk for COVID-19-related complications. Data supporting …

… The results were valid in vaccinated or unvaccinated high-risk individuals with COVID-19.
Data … and safety of nirmatrelvir-ritonavir and help improve treatment guidelines for COVID-19. …

… evaluate the use and adverse effects of nirmatrelvir/ritonavir in SOTRs and explore feasible
… suggest that nirmatrelvir/ritonavir could be a feasible treatment option for COVID-19 in SOTRs…

… Multivariable logistic regression models controlled for age, sex, race/ethnicity, chronic
conditions, and COVID-19 vaccination status. We found that participants who took …

… Treatment should start as soon as possible after a confirmed diagnosis of COVID-19,
ideally within 5 days of symptom onset. Although observational safety data for ritonavir in …

… COVID-19 patients, 18 of which received a complete combination of two antivirals (remdesivir
plus nirmatrelvir/ritonavir or … patient treated with a combination of nirmatrelvir/ritonavir (N/r) …

… Patients received nirmatrelvir (300 mg) plus ritonavir (100 mg) or placebo every 12 hours
for 5 days. Over an average of 27 days, the patients in the nirmatrelvir–ritonavir group had a …

… “true” incidence of COVID-19 rebound between the nirmatrelvir-ritonavir and molnupiravir
… medications that interact with nirmatrelvir-ritonavir were administered molnupiravir instead. …